Aarhus University Seal / Aarhus Universitets segl

Daniel Otzen

Biochemical mechanisms of aggregation in TGFBI-linked corneal dystrophies

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperReviewResearchpeer-review

  • Nadia Sukusu Nielsen
  • Ebbe Toftgaard Poulsen
  • ,
  • Marie V Lukassen, Biomolecular Mass Spectrometry and Proteomics, Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, Utrecht, the Netherlands.
  • ,
  • Connie Chao Shern, Avellino Labs USA, Menlo Park, USA., Ulster University
  • ,
  • Emilie Hage Mogensen
  • Christian E Weberskov
  • Larry DeDionisio, Avellino Labs USA, Menlo Park, USA.
  • ,
  • Leif Schauser, QIAGEN Aarhus A/S, Aarhus, Denmark.
  • ,
  • Tara C B Moore, Ulster University, Avellino Labs USA, Menlo Park, USA.
  • ,
  • Daniel E Otzen
  • Jesper Hjortdal
  • Jan J Enghild

Transforming growth factor-β-induced protein (TGFBIp), an extracellular matrix protein, is the second most abundant protein in the corneal stroma. In this review, we summarize the current knowledge concerning the expression, molecular structure, binding partners, and functions of human TGFBIp. To date, 74 mutations in the transforming growth factor-β-induced gene (TGFBI) are associated with amyloid and amorphous protein deposition in TGFBI-linked corneal dystrophies. We discuss the current understanding of the biochemical mechanisms of TGFBI-linked corneal dystrophies and propose that mutations leading to granular corneal dystrophy (GCD) decrease the solubility of TGFBIp and affect the interactions between TGFBIp and components of the corneal stroma, whereas mutations associated with lattice corneal dystrophy (LCD) lead to a destabilization of the protein that disrupts proteolytic turnover, especially by the serine protease HtrA1. Future research should focus on TGFBIp function in the cornea, confirmation of the biochemical mechanisms in vivo, and the development of disease models. Future therapies for TGFBI-linked corneal dystrophies might include topical agents that regulate protein aggregation or gene therapy that targets the mutant allele by CRISPR/Cas9 technology.

Original languageEnglish
Article number100843
JournalProgress in Retinal and Eye Research
Volume77
ISSN1350-9462
DOIs
Publication statusPublished - Jul 2020

See relations at Aarhus University Citationformats

ID: 177867605